The diaTribe Foundation

Thanksgiving is a time for gratitude and good food, but for people living with diabetes, it can also come with unique challenges. From navigating carb-heavy meals to managing glucose levels, the holiday can be tricky to balance. This article shares how one person with type 1 diabetes approaches the holiday with moderation, planning, and self-compassion. Whether it’s loading up on veggies first, getting some morning exercise, or pre-bolusing for long meals, these tips might help you too. Read more here: https://bit.ly/3CEvmIJ #DiabetesManagement #HolidayTips #ThanksgivingWithDiabetes #DiabetesCare

Latent Autoimmune Diabetes in Adults (LADA) is an often-overlooked form of type 1 diabetes that can be mistaken for type 2 diabetes. Many adults with LADA face delayed treatment and misdiagnosis because the condition doesn’t immediately require insulin. 🔎 Proper diagnosis is crucial to avoid complications like diabetic ketoacidosis and to ensure the best care. Learn about the symptoms, the importance of testing, and how to advocate for your health if you suspect a misdiagnosis. Read the full article: https://bit.ly/4g0xgS5 #DiabetesCare #LADA #Type1Diabetes #DiabetesAwareness #PatientAdvocacy

👁️ Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME) are often discussed together, but they are distinct diabetes-related eye conditions. DR refers to damage to the retina’s blood vessels, while DME specifically involves swelling in the macula, which is crucial for sharp, detailed vision. Both conditions can lead to vision loss if left untreated, but with regular screening, proper glucose management, and timely treatment, many people with diabetes can preserve their vision. Learn the differences between DR and DME and explore how to protect your eye health: https://bit.ly/3ZhmVvI #DiabetesManagement #EyeHealth #DiabetesResearch #DiabeticRetinopathy #DiabeticMacularEdema

TECH UPDATE! 🚨 Dexcom and smart ring maker ŌURA have announced plans to integrate continuous glucose monitoring with health and fitness data. Get the full details - https://bit.ly/4fiJa9u

Can a cholesterol-lowering drug help prevent diabetes-related retinopathy from worsening? Researchers are investigating fenofibrate in a groundbreaking clinical trial for individuals with type 1 or type 2 diabetes. This study could redefine care for retinopathy, offering a less invasive option to protect vision and improve quality of life for millions. Participants will be followed for six years to assess the drug’s effectiveness in slowing disease progression and reducing the need for more invasive treatments. Learn more about this important trial and see if you’re eligible to participate. 🔗 Read the full article on our website: https://bit.ly/4fERPDM #DiabetesResearch #ClinicalTrials #EyeHealth #DiabetesInnovation #Retinopathy

🎈💙 This National Diabetes Awareness Month, we’re proud to join the #BlueBalloonChallenge alongside our sponsors and partners at Medtronic to spotlight the many challenges people with diabetes face every day. From navigating daily management to overcoming unexpected obstacles, the resilience of the diabetes community inspires us all. #DiabetesAwareness #NationalDiabetesAwarenessMonth #BlueBalloonChallenge #DiabetesCommunity

🚨We’re back with three key time in range research findings! 🚨 As CGM use increases worldwide, research about how CGM metrics help people with diabetes and healthcare professionals is growing along with it. We’ve updated timeinrange.org’s research database with some of the latest, most compelling research that shows why metrics like time in range are imperative in diabetes management—check out the studies at https://lnkd.in/eWGm54ax. What we want to highlight 👇 - Using the AGP report can improve time in range, A1C, and time above range outcomes. Studies show that utilizing the AGP report is empowering to people with diabetes, and with more knowledge comes more empowerment to take action and become engaged in their own care. - People with Type 2 diabetes can benefit from CGM. New research suggests CGM metrics can help detect progression, reduce healthcare visits, and improve management in people with type 2. - Researchers are looking into whether CGMs might be able to help identify those at risk of type 1 diabetes and monitor progression, detect gestational diabetes earlier, and more! All of this proves what we know—it is time for time in range. Find these studies and more at https://lnkd.in/eWGm54ax. #TimeInRange #DiabetesNews 

🚨 1 in 6 U.S. adults have diabetes—and many don’t even know it. In a powerful call to action, our CEO, Jim Carroll, breaks down the latest CDC data and urges everyone to prioritize prevention and get screened. Early detection isn’t just important—it can save lives. Read Jim’s insights and learn how you can take control of your health: https://bit.ly/4hVmChj #DiabetesAwareness #GetScreened #KnowYourRisk

In part 2 of our 3-part series- Russ and Eritrea M., people with diabetes affected by Diabetic Macular Edema, discuss the importance of open communication for clarification and optimism when seeing your health care team. “Always do your best to feel empowered to ask questions of your health care team”. Link to article-  https://bit.ly/3CD0I2l

Full results from the SURMOUNT-1 trial reveal that tirzepatide (Zepbound/Mounjaro) reversed prediabetes in 94% of participants and prevented progression to type 2 diabetes in nearly 99%. These findings highlight a potential game-changer in managing prediabetes and obesity. Explore the study details and its implications: https://bit.ly/3CBFZMb #DiabetesCare #Prediabetes #Tirzepatide #HCP